|
1
|
Bavikar RR, Kulkarni RK, Rathod AD and
Hastak MS: Idiopathic myelofibrosis in an infant. Indian J Pediatr.
78:734–736. 2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bhagwat N, Levine RL and Koppikar P:
Sensitivity and resistance of JAK2 inhibitors to myeloproliferative
neoplasms. Int J Hematol. 97:695–702. 2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cox MC, Panetta P, Venditti A, Abruzzese
E, Del Poeta G, Cantonetti M and Amadori S: New reciprocal
translocation t(6;10) (q27;q11) associated with idiopathic
myelofibrosis and eosinophilia. Leuk Res. 25:349–351.
2001.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tognon R, Gasparotto EP, Leroy JM,
Oliveira GL, Neves RP, Carrara Rde C, Kashima S, Covas DT, Santana
M, Souto EX, et al: Differential expression of apoptosis-related
genes from death receptor pathway in chronic myeloproliferative
diseases. J Clin Pathol. 64:75–82. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bouabdallah R, Coso D, Gonzague-Casabianca
L, Alzieu C, Resbeut M and Gastaut JA: Safety and efficacy of
splenic irradiation in the treatment of patients with idiopathic
myelofibrosis: A report on 15 patients. Leuk Res. 24:491–495.
2000.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kerbauy DM, Gooley TA, Sale GE, Flowers
ME, Doney KC, Georges GE, Greene JE, Linenberger M, Petersdorf E,
Sandmaier BM, et al: Hematopoietic cell transplantation as curative
therapy for idiopathic myelofibrosis, advanced polycythemia vera,
and essential thrombocythemia. Biol Blood Marrow Transplant.
13:355–365. 2007.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wolf D, Rudzki J and Gastl G: Current
treatment concepts of Philadelphia-negative MPN. Curr Cancer Drug
Targets. 11:44–55. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cervantes F: Modern management of
myelofibrosis. Br J Haematol. 128:583–592. 2005.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Cervantes F, Barosi G, Demory JL, Reilly
J, Guarnone R, Dupriez B, Pereira A and Montserrat E: Myelofibrosis
with myeloid metaplasia in young individuals: Disease
characteristics, prognostic factors and identification of risk
groups. Br J Haematol. 102:684–690. 1998.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Rumi E: Familial chronic
myeloproliferative disorders: The state of the art. Hematol Oncol.
26:131–138. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Rumi E, Passamonti F, Della Porta MG,
Elena C, Arcaini L, Vanelli L, Del Curto C, Pietra D, Boveri E,
Pascutto C, et al: Familial chronic myeloproliferative disorders:
Clinical phenotype and evidence of disease anticipation. J Clin
Oncol. 25:5630–5635. 2007.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Quintas-Cardama A and Verstovsek S:
Molecular pathways: Jak/STAT pathway: Mutations, inhibitors, and
resistance. Clin Cancer Res. 19:1933–1940. 2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Bennett M and Stroncek DF: Recent advances
in the bcr-abl negative chronic myeloproliferative diseases. J
Transl Med. 4(41)2006.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ishida S, Akiyama H, Umezawa Y, Okada K,
Nogami A, Oshikawa G, Nagao T and Miura O: Mechanisms for mTORC1
activation and synergistic induction of apoptosis by ruxolitinib
and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing
leukemic cells including newly established PVTL-2. Oncotarget.
9:26834–26851. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
He ZP, Tian HY, Tan M and Wu Y: Clinical
Analysis of Driver Mutations in Patients with Ph Negative
Myeloproliferative Neoplasms. Zhongguo Shi Yan Xue Ye Xue Za Zhi.
26:842–848. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
16
|
Tefferi A: Primary myelofibrosis: 2017
update on diagnosis, risk-stratification, and management. Am J
Hematol. 91:1262–1271. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kvasnicka HM: The differential diagnosis
of classical myeloproliferative neoplasms (MPN): The updated WHO
criteria. Rinsho Ketsueki. 60:1166–1175. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Baxter EJ, Scott LM, Campbell PJ, East C,
Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N,
et al: Acquired mutation of the tyrosine kinase JAK2 in human
myeloproliferative disorders. Lancet. 365:1054–1561.
2005.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ayatollahi H, Keramati MR, Shirdel A,
Kooshyar MM, Raiszadeh M, Shakeri S and Sadeghian MH: BCR-ABL
fusion genes and laboratory findings in patients with chronic
myeloid leukemia in northeast Iran. Caspian J Intern Med. 9:65–70.
2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Fatema K, Tabassum S, Nessa A and Jahan M:
Development and evaluation of an in-house ELISA to detect hepatitis
B virus surface antigen in resource-limited settings. Bangladesh
Med Res Counc Bull. 39:65–8. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Friedrich-Rust M, Rosenberg W, Parkes J,
Herrmann E, Zeuzem S and Sarrazin C: Comparison of ELF, FibroTest
and FibroScan for the non-invasive assessment of liver fibrosis.
BMC Gastroenterol. 10(103)2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Bain BJ: Bone marrow aspiration. J Clin
Pathol. 54:657–63. 2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wang YL, Wang T, Xu F, Gang Y and Wang J:
Analysis of DEK-CAN fusion gene expression in acute myeloid
leukemia patients with 6; 9 chromosome translocation. Zhongguo Shi
Yan Xue Ye Xue Za Zhi. 14:232–236. 2006.PubMed/NCBI(In Chinese).
|
|
24
|
Khan SA, Yasmeen S, Adel H, Adil SO, Huda
F and Khan S: Sonographic evaluation of normal liver, spleen, and
renal parameters in adult population: A multicenter study. J Coll
Physicians Surg Pak. 28:834–839. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Humphries JE: Dry tap bone marrow
aspiration: Clinical significance. Am J Hematol. 35:247–250.
1990.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hirri HM and Green RJ: Myelodysplasia and
bone marrow fibrosis treated with calcitriol and venesection. Leuk
Lymphoma. 43:1489–1491. 2002.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Guo Y, Xu WW, Dong L, Huang N and Bi KH:
Progression of primary myelofibrosis to polycythemia vera: A case
report. Medicine (Baltimore). 96(e7464)2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tefferi A: The forgotten
myeloproliferative disorder: Myeloid metaplasia. Oncologist.
8:225–231. 2003.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Narendran A, Hawkins LM, Ganjavi H, Vanek
W, Gee MF, Barlow JW, Johnson G, Malkin D and Freedman MH:
Characterization of bone marrow stromal abnormalities in a patient
with constitutional trisomy 8 mosaicism and myelodysplastic
syndrome. Pediatr Hematol Oncol. 21:209–221. 2004.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tavares RS, Nonino A, Pagnano KBB,
Nascimento ACKVD, Conchon M, Fogliatto LM, Funke VA, Bendit I,
Clementino NC, Chauffaille MLLF, et al: Guideline on
myeloproliferative neoplasms: Associacão brasileira de hematologia,
hemoterapia E terapia cellular: Project guidelines: Associação
médica brasileira-2019. Hematol Transfus Cell Ther. 41
(Suppl):S1–S73. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Alshemmari SH, Rajan R and Emadi A:
Molecular pathogenesis and clinical significance of driver
mutations in primary myelofibrosis: A review. Med Princ Pract.
25:501–509. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Skoda R and Prchal JT: Lessons from
familial myeloproliferative disorders. Semin Hematol. 42:266–273.
2005.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Malak S, Labopin M, Saint-Martin C,
Bellanne-Chantelot C and Najman A: French Group of Familial
Myeloproliferative Disorders. Long term follow up of 93 families
with myeloproliferative neoplasms: Life expectancy and implications
of JAK2V617F in the occurrence of complications. Blood Cells Mol
Dis. 49:170–176. 2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Perez-Encinas M, Bello JL, Perez-Crespo S,
De Miguel R and Tome S: Familial myeloproliferative syndrome. Am J
Hematol. 46:225–229. 1994.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Sheikha A: Fatal familial infantile
myelofibrosis. J Pediatr Hematol Oncol. 26:164–168. 2004.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Bruchova H, Merkerova M and Prchal JT:
Aberrant expression of microRNA in polycythemia vera.
Haematologica. 93:1009–1016. 2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Panagiota V, Thol F, Markus B, Fehse B,
Alchalby H, Badbaran A, Lehmann U, Koenecke C, Shahswar R,
Chaturvedi A, et al: Prognostic effect of calreticulin mutations in
patients with myelofibrosis after allogeneic hematopoietic stem
cell transplantation. Leukemia. 28:1552–1555. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Saint-Martin C, Leroy G, Delhommeau F,
Panelatti G, Dupont S, James C, Plo I, Bordessoule D, Chomienne C,
Delannoy A, et al: Analysis of the ten-eleven translocation 2
(TET2) gene in familial myeloproliferative neoplasms. Blood.
114:1628–1632. 2009.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Stein BL, Williams DM, O'Keefe C, Rogers
O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA
and Moliterno AR: Disruption of the ASXL1 gene is frequent in
primary, post-essential thrombocytosis and post-polycythemia vera
myelofibrosis, but not essential thrombocytosis or polycythemia
vera: Analysis of molecular genetics and clinical phenotypes.
Haematologica. 96:1462–1469. 2011.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Guglielmelli P, Biamonte F, Score J,
Hidalgo-Curtis C, Cervantes F, Maffioli M, Fanelli T, Ernst T,
Winkelman N, Jones AV, et al: EZH2 mutational status predicts poor
survival in myelofibrosis. Blood. 118:5227–5234. 2011.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Guglielmelli P, Lasho TL, Rotunno G, Score
J, Mannarelli C, Pancrazzi A, Biamonte F, Pardanani A, Zoi K,
Reiter A, et al: The number of prognostically detrimental mutations
and prognosis in primary myelofibrosis: An international study of
797 patients. Leukemia. 28:1804–1810. 2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Tefferi A: Primary myelofibrosis: 2014
update on diagnosis, risk-stratification, and management. Am J
Hematol. 89:915–925. 2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Lasho TL, Finke CM, Hanson CA, Jimma T,
Knudson RA, Ketterling RP, Pardanani A and Tefferi A: SF3B1
mutations in primary myelofibrosis: Clinical, histopathology and
genetic correlates among 155 patients. Leukemia. 26:1135–1137.
2012.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Tefferi A, Finke CM, Lasho TL, Wassie EA,
Knudson R, Ketterling RP, Hanson CA and Pardanani A: U2AF1
mutations in primary myelofibrosis are strongly associated with
anemia and thrombocytopenia despite clustering with JAK2V617F and
normal karyotype. Leukemia. 28:431–433. 2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Tanaka H, Takeuchi M, Takeda Y, Sakai S,
Abe D, Ohwada C, Sakaida E, Shimizu N, Saito Y, Miyagi S, et al:
Identification of a novel TEL-Lyn fusion gene in primary
myelofibrosis. Leukemia. 24:197–200. 2010.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Kralovics R and Skoda RC: Molecular
pathogenesis of Philadelphia chromosome negative myeloproliferative
disorders. Blood Rev. 19:1–13. 2005.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Tognon R, Gasparotto EP, Neves RP, Nunes
NS, Ferreira AF, Palma PV, Kashima S, Covas DT, Santana M, Souto
EX, et al: Deregulation of apoptosis-related genes is associated
with PRV1 overexpression and JAK2 V617F allele burden in Essential
Thrombocythemia and Myelofibrosis. J Hematol Oncol.
5(2)2012.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Kaushansky K: The chronic
myeloproliferative disorders and mutation of JAK2: Dameshek's 54
year old speculation comes of age. Best Pract Res Clin Haematol.
20:5–12. 2007.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Latagliata R, Polverelli N, Tieghi A,
Palumbo GA, Breccia M, Sabattini E, Villari L, Riminucci M, Valli
R, Catani L, et al: Comparison of JAK2V617F-positive
essential thrombocythaemia and early primary myelofibrosis: The
impact of mutation burden and histology. Hematol Oncol. 36:269–275.
2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Schwartz DM, Kanno Y, Villarino A, Ward M,
Gadina M and O'Shea JJ: JAK inhibition as a therapeutic strategy
for immune and inflammatory diseases. Nat Rev Drug Discov.
17(78)2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Verstovsek S, Kantarjian H, Mesa RA,
Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS,
Bradley EC, Erickson-Viitanen S, et al: Safety and efficacy of
INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J
Med. 363:1117–1127. 2010.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Hu M, Xu C, Yang C, Zuo H, Chen C, Zhang
D, Shi G, Wang W, Shi J and Zhang T: Discovery and evaluation of
ZT55, a novel highly-selective tyrosine kinase inhibitor of
JAK2V617F against myeloproliferative neoplasms. J Exp
Clin Cancer Res. 38(49)2019.PubMed/NCBI View Article : Google Scholar
|
